Positive News SentimentPositive NewsNASDAQ:MDXH MDxHealth (MDXH) Stock Price, News & Analysis $3.48 -0.06 (-1.69%) Closing price 04:00 PM EasternExtended Trading$3.49 +0.01 (+0.29%) As of 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About MDxHealth Stock (NASDAQ:MDXH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MDxHealth alerts:Sign Up Key Stats Today's Range$3.46▼$3.5550-Day Range$2.14▼$3.6252-Week Range$1.35▼$3.81Volume78,135 shsAverage Volume93,405 shsMarket Capitalization$164.57 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingBuy Company Overview MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management. MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx. ConfirmMDx is an epigenetic assay performed on prostate biopsy tissue to identify men at risk of harboring occult high-grade prostate cancer following a negative biopsy result. SelectMDx is a non-invasive urine test designed to assess the likelihood of clinically significant prostate cancer before an initial biopsy, helping to reduce unnecessary procedures. Both tests are performed in MDxHealth’s CLIA-certified laboratory in the United States and its ISO-certified laboratory in Europe, and are used by urologists worldwide to guide biopsy and treatment decisions. Founded in 2003, MDxHealth has established a global footprint, serving patients and healthcare providers across North America, Europe and select international markets through direct lab services and strategic partnerships. The company is led by President and CEO Caroline Palm, who brings extensive experience in molecular diagnostics and life sciences. MDxHealth is publicly traded on the Nasdaq under the ticker symbol MDXH.AI Generated. May Contain Errors. Read More MDxHealth Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreMDXH MarketRank™: MDxHealth scored higher than 64% of companies evaluated by MarketBeat, and ranked 355th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingMDxHealth has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Upside PotentialMDxHealth has a consensus price target of $7.00, representing about 101.1% upside from its current price of $3.48.Amount of Analyst CoverageMDxHealth has only been the subject of 1 research reports in the past 90 days.Read more about MDxHealth's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for MDxHealth are expected to grow in the coming year, from ($1.15) to ($0.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MDxHealth is -3.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MDxHealth is -3.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMDxHealth has a P/B Ratio of 11.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about MDxHealth's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.16% of the float of MDxHealth has been sold short.Short Interest Ratio / Days to CoverMDxHealth has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MDxHealth has recently decreased by 47.06%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMDxHealth does not currently pay a dividend.Dividend GrowthMDxHealth does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.16% of the float of MDxHealth has been sold short.Short Interest Ratio / Days to CoverMDxHealth has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MDxHealth has recently decreased by 47.06%, indicating that investor sentiment is improving significantly. News and Social Media4.3 / 5News Sentiment1.72 News SentimentMDxHealth has a news sentiment score of 1.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for MDxHealth this week, compared to 1 article on an average week.Search Interest3 people have searched for MDXH on MarketBeat in the last 30 days. MarketBeat Follows2 people have added MDxHealth to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MDxHealth insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.70% of the stock of MDxHealth is held by insiders.Read more about MDxHealth's insider trading history. Receive MDXH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MDxHealth and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MDXH Stock News HeadlinesMDxHealth (MDXH) Gets a Buy from Lake StreetAugust 30, 2025 | theglobeandmail.comMDxHealth (MDXH) Gets a Buy from TD CowenAugust 30, 2025 | theglobeandmail.comNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 trillion calculations per second. Elon Musk and Nvidia’s Jensen Huang are now teaming up to deploy one million of these chips inside what could become the most advanced AI machine on the planet. But according to James Altucher, the real opportunity isn’t in Tesla or Nvidia. He’s uncovered a little-known company that Musk, Nvidia, and even 98% of the Fortune 500 already rely on to make AI 2.0 possible. Nvidia’s CEO has even called this company “essential” to their expansion.September 10 at 2:00 AM | Paradigm Press (Ad)MDxHealth (MDXH) Receives a Buy from BTIGAugust 30, 2025 | theglobeandmail.comMdxhealth Reports Strong Q2 Growth and Strategic AcquisitionAugust 15, 2025 | msn.comMDxHealth Reports Strong Revenue Growth in 2025 Interim ResultsAugust 14, 2025 | msn.comInsights Ahead: MDxHealth's Quarterly EarningsAugust 14, 2025 | benzinga.comMdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-TechneAugust 5, 2025 | globenewswire.comSee More Headlines MDXH Stock Analysis - Frequently Asked Questions How have MDXH shares performed this year? MDxHealth's stock was trading at $2.37 on January 1st, 2025. Since then, MDXH stock has increased by 46.8% and is now trading at $3.48. How were MDxHealth's earnings last quarter? MDxHealth SA (NASDAQ:MDXH) posted its quarterly earnings data on Tuesday, August, 5th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.02. The business had revenue of $26.60 million for the quarter, compared to analysts' expectations of $26.60 million. MDxHealth had a negative net margin of 34.98% and a negative trailing twelve-month return on equity of 374.98%. Read the conference call transcript. When did MDxHealth's stock split? MDxHealth's stock reverse split on Friday, December 29th 2023.The 1-10 reverse split was announced on Monday, October 2nd 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did MDxHealth IPO? MDxHealth (MDXH) raised $45 million in an initial public offering on Thursday, November 4th 2021. The company issued 3,750,000 shares at a price of $12.00 per share. Who are MDxHealth's major shareholders? MDxHealth's top institutional investors include Samjo Management LLC (3.25%), Delta Investment Management LLC (0.37%) and FreeGulliver LLC (0.26%). View institutional ownership trends. How do I buy shares of MDxHealth? Shares of MDXH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MDxHealth own? Based on aggregate information from My MarketBeat watchlists, some other companies that MDxHealth investors own include Cognition Therapeutics (CGTX), LAVA Therapeutics (LVTX), Coeptis Therapeutics (COEP), PHX Minerals (PHX), PayPal (PYPL), Arcadia Biosciences (RKDA) and Alimera Sciences (ALIM). Company Calendar Last Earnings8/05/2025Today9/10/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MEDICAL INFO SYS Sub-IndustryN/A Current SymbolNASDAQ:MDXH CIK1872529 Webmdxhealth.com Phone324-364-2070Fax32042597875Employees300Year FoundedN/APrice Target and Rating Average Price Target for MDxHealth$7.00 High Price Target$8.00 Low Price Target$6.00 Potential Upside/Downside+100.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.07 million Net Margins-34.98% Pretax Margin-40.47% Return on Equity-374.98% Return on Assets-21.97% Debt Debt-to-Equity Ratio13.81 Current Ratio1.31 Quick Ratio1.22 Sales & Book Value Annual Sales$90.05 million Price / Sales1.83 Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book11.26Miscellaneous Outstanding Shares47,290,000Free Float46,484,000Market Cap$165.04 million OptionableNot Optionable Beta1.49 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:MDXH) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredWall Street Legend Issues Urgent AI Stock Warning'Hidden AI' is taking the U.S. stock market by storm.Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MDxHealth SA Please log in to your account or sign up in order to add this asset to your watchlist. Share MDxHealth With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.